SCP
CUE icon

Silverleafe Capital Partners’s Cue Biopharma CUE Stock Holding History

Silverleafe Capital Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-467
Closed -$166K – 62
2018
Q2 		$166K Buy
+467
New +$186K 0.1% 59

Other funds holding CUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Silverleafe Capital Partners's CUE Position: Q3 2018 in Review

Silverleafe Capital Partners sold out of Cue Biopharma (CUE) in Q3 2018, closing a stake of 467 shares — an estimated $166K sold.

Silverleafe Capital Partners first reported a position in CUE in Q2 2018 and held it in 1 quarter. The position peaked at $166K in Q2 2018. 37 funds tracked by Wall St. Rank hold CUE as of Q3 2018.

  • Silverleafe Capital Partners reported no remaining Cue Biopharma position as of Q3 2018 after selling out during the quarter.
  • Silverleafe Capital Partners sold 467 Cue Biopharma shares in Q3 2018, an estimated $166K.
  • Silverleafe Capital Partners first reported a position in Cue Biopharma in Q2 2018 and held it in 1 quarter.
  • Silverleafe Capital Partners's Cue Biopharma position peaked at $166K in Q2 2018.
  • 37 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2018.

Based on Silverleafe Capital Partners's 13F filing for Q3 2018, filed 5 Oct 2018.